Fructose-1,6-bisphosphate protects against Zymosan-induced acute lung injury in mice.
It has been previously showed that fructose-1,6-bisphosphate (FBP) has anti-inflammatory and immunomodulatory effects on several experimental inflammation models. However, the effects and mechanism of FBP on Zymosan-induced acute lung injury (ALI) in mice had not been tested. In this study, our aim was to assess the anti-inflammatory activities of FBP on Zymosan-induced ALI. We found that in vivo treatment with FBP (500 mg/kg i.p.) markedly decreased the nitric oxide (NO) levels in the lungs and significantly reduced bronchoalveolar lavage fluid total cell and neutrophil counts and protein exudation after Zymosan challenge. Furthermore, FBP inhibited inducible nitric oxide synthase (iNOS) activities in RAW macrophages. Meanwhile, FBP did not inhibit the cyclooxigenase 2, interleukin-6, and nuclear factor kappa B transcription. Taken together, these results suggest that FBP shows anti-inflammatory effects through inhibiting lung edema, NO, and iNOS activities.
Laboratório de Microbiologia Clínica, Ciências da Saúde, Centro Universitário Franciscano, UNIFRA, Rua dos Andradas 1614, Sala 115, 97010-032 Santa Maria, Rio Grande do Sul, Brazil. robertochrist@gmail.com
Roberto Christ Vianna
RC
Santos
Rafael Noal
RN
Moresco
Miguel Angel
MA
Peña Rico
Antonio R García
AR
Susperregui
Jose Luis
JL
Rosa
Ramon
R
Bartrons
Francesc
F
Ventura
Débora Nunes
DN
Mário
Sydney Hartz
SH
Alves
Etiane
E
Tatsch
Helena
H
Kober
Ricardo Obalski
RO
de Mello
Patrícia
P
Scherer
Jarbas Rodrigues
JR
de Oliveira
D055371:Acute Lung Injury / Q000139:chemically induced / Q000188:drug therapy*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D051546:Cyclooxygenase 2 / Q000096:biosynthesis / Q000235:genetics; D004487:Edema / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D005635:Fructosediphosphates / Q000494:pharmacology* / Q000627:therapeutic use; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000378:metabolism; D008297:Male; D051379:Mice; D016328:NF-kappa B / Q000096:biosynthesis / Q000235:genetics; D009504:Neutrophils; D009569:Nitric Oxide / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis* / Q000378:metabolism; D014158:Transcription, Genetic; D015054:Zymosan
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005635:Fructosediphosphates; D015850:Interleukin-6; D016328:NF-kappa B; D009569:Nitric Oxide; D015054:Zymosan; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; C029063:fructose-1,6-diphosphate